Abstract
Tetherin (BST-2 or CD317) is an interferon-inducible cellular factor that prevents the detachment of enveloped viruses from infected cells. The primate lentiviruses have evolved different countermeasures to tetherin. The majority of SIVs use Nef to antagonize the tetherin proteins of their nonhuman primate hosts. However, due to the absence of sequences in human tetherin required for antagonism by Nef, HIV-1 Vpu and HIV-2 Env evolved to serve this function in humans. We recently identified compensatory changes in the Env cytoplasmic domain of a pathogenic nef-deleted SIV that confers resistance to rhesus macaque tetherin. These observations highlight the extraordinary plasticity of the primate lentiviruses in adapting to the tetherin proteins of their respective hosts, and reveal a prominent role for tetherin in shaping the evolution of the primate lentiviruses.
Keywords: Primate, monkey, SIV, HIV, Nef, Env, Vpu, interferon, CD317, HM1.24, restriction factor, innate immunity
Current HIV Research
Title:Adaptation of Human and Simian Immunodeficiency Viruses for Resistance to Tetherin/BST-2
Volume: 10 Issue: 4
Author(s): Ruth Serra-Moreno and David T. Evans
Affiliation:
Keywords: Primate, monkey, SIV, HIV, Nef, Env, Vpu, interferon, CD317, HM1.24, restriction factor, innate immunity
Abstract: Tetherin (BST-2 or CD317) is an interferon-inducible cellular factor that prevents the detachment of enveloped viruses from infected cells. The primate lentiviruses have evolved different countermeasures to tetherin. The majority of SIVs use Nef to antagonize the tetherin proteins of their nonhuman primate hosts. However, due to the absence of sequences in human tetherin required for antagonism by Nef, HIV-1 Vpu and HIV-2 Env evolved to serve this function in humans. We recently identified compensatory changes in the Env cytoplasmic domain of a pathogenic nef-deleted SIV that confers resistance to rhesus macaque tetherin. These observations highlight the extraordinary plasticity of the primate lentiviruses in adapting to the tetherin proteins of their respective hosts, and reveal a prominent role for tetherin in shaping the evolution of the primate lentiviruses.
Export Options
About this article
Cite this article as:
Serra-Moreno Ruth and T. Evans David, Adaptation of Human and Simian Immunodeficiency Viruses for Resistance to Tetherin/BST-2, Current HIV Research 2012; 10 (4) . https://dx.doi.org/10.2174/157016212800792496
DOI https://dx.doi.org/10.2174/157016212800792496 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine Recent Trends in the Pharmacological Activity of Isoprenyl Phenolics
Current Medicinal Chemistry Quassinoids: From Traditional Drugs to New Cancer Therapeutics
Current Medicinal Chemistry Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Application of SMILES Notation Based Optimal Descriptors in Drug Discovery and Design
Current Topics in Medicinal Chemistry Flavonoids as Anticancer Agents: Structure-Activity Relationship Study
Current Medicinal Chemistry - Anti-Cancer Agents Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Platinum-Intercalator Conjugates: From DNA-Targeted Cisplatin Derivatives to Adenine Binding Complexes as Potential Modulators of Gene Regulation
Current Topics in Medicinal Chemistry New Generation of Oncolytic Herpes Virus
Current Cancer Therapy Reviews Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition The Neuroendocrine Component in Bladder Tumors
Current Medicinal Chemistry FDG-PET in Tuberculosis
Current Molecular Imaging (Discontinued) The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer
Current Cancer Drug Targets The Physiological Basis and Nutritional Function of Alpha-ketoglutarate
Current Protein & Peptide Science Update on Hsp90 Inhibitors in Clinical Trial
Current Topics in Medicinal Chemistry Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics The Use of Innovative Tools to Reproduce Human Cancer Translocations: Lessons from the CRISPR/Cas System
Current Biotechnology Connecting Small Molecules to Nuclear Receptor Pathways
Current Topics in Medicinal Chemistry